Laboratorios Richmond SACIF

Laboratorios Richmond SACIF Net Margin

The Net Profit Margin of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 25.98 %. In the previous year, Net Profit Margin was -27.80 % — a change of -193.43% (higher).

Net Margin

25.98 %

YoY

-193.43%

Last updated:

Net Profit Margin of Laboratorios Richmond SACIF is 2024 25.98 % . Net Profit Margin of Laboratorios Richmond SACIF was 2023 -27.80 % . It decreases by -193.43% higher compared to the previous year.

For Laboratorios Richmond SACIF, the net margin of 26.0% is up versus 7.9% a few years ago.

The Laboratorios Richmond SACIF Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
3.06 ARS
Jan 1, 2018
-11.87 ARS
Jan 1, 2019
2.99 ARS
Jan 1, 2020
7.87 ARS
Jan 1, 2021
3.56 ARS
Jan 1, 2022
0.88 ARS
Jan 1, 2023
-27.80 ARS
Jan 1, 2024
25.98 ARS
The Laboratorios Richmond SACIF Net Margin history
YEARNet MarginYoY
25.98 %-193.43%
-27.80 %-3,242.12%
0.88 %-75.14%
3.56 %-54.75%
7.87 %+163.14%
2.99 %-125.19%
-11.87 %-487.61%
3.06 %-72.36%
11.07 %+748.54%
1.31 %-29.94%
1.86 %+483,686.97%
0.00-97.75%
0.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

Net Profit Margin of Laboratorios Richmond SACIF is 25.98 % in 2024.

Net Profit Margin of Laboratorios Richmond SACIF changed from -27.80 % to 25.98 %, representing a -193.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Laboratorios Richmond SACIF with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF